2-phenyl-quinoline-4-carboxylic acid-(N'-phenyl-hydrazide)

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-phenyl-quinoline-4-carboxylic acid-(N'-phenyl-hydrazide)
• 英文别名: 2-Phenyl-chinolin-4-carbonsaeure-(N'-phenyl-hydrazid)；N',2-diphenylquinoline-4-carbohydrazide
• 化学式: C₂₂H₁₇N₃O
• 分子量: 339.396
• InChiKey: ADHPPIXJZYIQPG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  苯肼 、 alkaline earth salt of/the/ methylsulfuric acid 生成 2-phenyl-quinoline-4-carboxylic acid-(N'-phenyl-hydrazide)
  参考文献：
  名称：

  Rojahn; Schulten, Archiv der Pharmazie, 1926, p. 350

  摘要：

  DOI：

文献信息

• GPCR heteromer inhibitors and uses thereof
  申请人：GPCR THERAPEUTICS, INC.

  公开号：US10709763B2

  公开（公告）日：2020-07-14

  This invention relates to inhibitors of CXC receptor 4 (CXCR4)-G protein-coupled receptor (GPCR) heteromers (CXCR4-GPCR heteromers) associated with cancers, where CXCR4 forms a functional heteromer with other G protein-coupled receptors (GPCRx). More specifically, this invention relates to GPCRx that form heteromers with CXCR4, which upon co-stimulation with CXCR4 agonists and GPCRx agonists leads to enhanced signaling downstream of CXCR4. This invention also provides for the use of inhibitors of the interacting GPCR partner of the CXCR4-GPCRx heteromer or CXCR4-GPCRx heteromer-specific inhibitors including inhibitors of the formation of the CXCR4-GPCRx heteromer and CXCR4-GPCRx heteromer-specific antibodies, and in the diagnosis and/or therapy for cancer.

  本发明涉及与癌症相关的CXC受体4（CXCR4）-G蛋白偶联受体（GPCR）异构体（CXCR4-GPCR异构体）的抑制剂，其中CXCR4与其他G蛋白偶联受体（GPCRx）形成功能性异构体。更具体地说，本发明涉及与 CXCR4 形成异构体的 GPCRx，在 CXCR4 激动剂和 GPCRx 激动剂的共同刺激下，会导致 CXCR4 下游信号的增强。本发明还提供了CXCR4-GPCRx异构体相互作用GPCR伙伴的抑制剂或CXCR4-GPCRx异构体特异性抑制剂的用途，包括CXCR4-GPCRx异构体形成抑制剂和CXCR4-GPCRx异构体特异性抗体，以及在癌症诊断和/或治疗中的用途。
• GPCR HETEROMER INHIBITORS AND USES THEREOF
  申请人：GPCR Therapeutics, Inc.

  公开号：EP3727371A1

  公开（公告）日：2020-10-28
• [EN] TREATING NEUROMUSCULAR OR NEUROLOGIC DISEASE THROUGH REDUCING GABAERGIC AND/OR GLYCINERGIC INHIBITORY NEUROTRANSMITTER OVERSTIMULATION<br/>[FR] TRAITEMENT DE MALADIE NEUROMUSCULAIRE OU NEUROLOGIQUE PAR RÉDUCTION DE LA SURSTIMULATION DES NEUROTRANSMETTEURS INHIBITEURS GABAERGIQUES ET/OU GLYCINERGIQUE
  申请人：RY PHARMA B V

  公开号：WO2016114655A1

  公开（公告）日：2016-07-21

  The disclosure provides novel methods of treating neuromuscular or neurologic disease, for example, Amyotrophic lateral sclerosis (ALS), through reducing GABAergic and Glycinergic inhibitory neurotransmitter activity overstimulation. Pharmaceutical compositions comprising one or more compounds capable of reducing Glycinergic activity and/or one or more compounds capable of reducing GABAergic activity are also provided. Methods for treating one or more symptoms caused by inhibitory neurotransmitter overstimulation (e.g., muscle wasting, loss of muscle function, loss of muscle coordination, respiratory depression, dysphagia, dysarthria, eye movement difficulties, oculomotor gaze palsy, supranuclear gaze palsy, bladder dysfunction and gastrointestinal dysfunction) in an individual afflicted with ALS or an ALS- like disorder are also provided.
• [EN] TREATING NEUROMUSCULAR OR NEUROLOGIC DISEASE THROUGH REDUCING GABAERGIC AND/OR GLYCINERGIC INHIBITORY NEUROTRANSMITTER OVERSTIMULATION<br/>[FR] TRAITEMENT DE MALADIE NEUROMUSCULAIRE OU NEUROLOGIQUE PAR RÉDUCTION DE LA SURSTIMULATION DES NEUROTRANSMETTEURS INHIBITEURS GABAERGIQUES ET/OU GLYCINERGIQUES
  申请人：RY PHARMA B V

  公开号：WO2017065602A1

  公开（公告）日：2017-04-20

  The disclosure provides novel methods of treating neuromuscular or neurologic disease, for example, Amyotrophic lateral sclerosis (ALS), through reducing GABAergic and Glycinergic inhibitory neurotransmitter activity overstimulation. Pharmaceutical compositions comprising one or more compounds capable of reducing Glycinergic activity and/or one or more compounds capable of reducing GABAergic activity are also provided. Pharmaceutical compositions comprising Penicillin G and, optionally, glucocorticoid are especially useful in the present invention. Methods for treating one or more symptoms caused by inhibitory neurotransmitter overstimulation (e.g., muscle wasting, loss of muscle function, loss of muscle coordination, respiratory depression, dysphagia, dysarthria, eye movement difficulties, oculomotor gaze palsy, supranuclear gaze palsy, bladder dysfunction and gastrointestinal dysfunction) in an individual afflicted with ALS or an ALS- like disorder are also provided.